Predict your next investment

Holding Company
HEALTHCARE | Pharmaceuticals / Drugs
pernixtx.com

See what CB Insights has to offer

Stage

Asset Sale | AssetsPurchased

About Pernix Therapeutics Holdings

Pernix Therapeutics Holdings is a specialty pharmaceutical business with a focus on acquiring, developing, and commercializing prescription drugs primarily for the U.S. market. The company is currently focused on the therapeutic areas of pain and neurology, and has an interest in expanding into additional specialty segments.

Pernix Therapeutics Holdings Headquarter Location

10 North Park Place Suite 201

Morristown, New Jersey, 07960,

United States

800-793-2145

Latest Pernix Therapeutics Holdings News

Currax Holdings LLC’s $75.6 Million Acquisition Of Pernix Assets

May 7, 2019

Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with the sale of substantially all of its assets to Currax Holdings LLC, an entity formed by affiliates of Highbridge Capital Management, LLC, for approximately $75.6 million, plus the assumption of certain liabilities. The sale was consummated through Pernix’s Chapter 11 bankruptcy. The sale of substantially all of Pernix’s assets through an accelerated in-court process was enabled by a comprehensive settlement negotiated among Pernix, Highbridge and the official committee of unsecured creditors appointed in Pernix’s bankruptcy and approved by the court on April 4, 2019. Pernix is pursuing confirmation of a plan of liquidation reflecting the settlement’s material terms. Pernix is a specialty pharmaceutical company, based in Morristown, New Jersey. Pernix’s core branded products included Zohydro ER with BeadTek, Silenor and Treximet. Guggenheim Securities, LLC served as Pernix’s investment banker and Ernst & Young LLP served as its financial adviser. Landis Rath & Cobb LLP served as Pernix’s Delaware counsel. The Davis Polk restructuring team included partners Marshall S. Huebner and Eli J. Vonnegut (Picture) and associates Christopher Robertson and Erik Jerrard. The corporate team included partner Michael Davis and associate Abraham Einhorn. The credit team included partner Jinsoo H. Kim and counsel Andrei Takhteyev. The litigation team included partner Elliot Moskowitz and associate Olga Kogan.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Pernix Therapeutics Holdings

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pernix Therapeutics Holdings is included in 1 Expert Collection, including Neuroscience.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

Pernix Therapeutics Holdings Patents

Pernix Therapeutics Holdings has filed 19 patents.

The 3 most popular patent topics include:

  • Lactams
  • Sedatives
  • Prodrugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/8/2019

9/1/2020

Sedatives, Hypnotics, Prodrugs, Lactams, Benzodiazepines

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/8/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/1/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Sedatives, Hypnotics, Prodrugs, Lactams, Benzodiazepines

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.